JP2016216493A - 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 - Google Patents
疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 Download PDFInfo
- Publication number
- JP2016216493A JP2016216493A JP2016140167A JP2016140167A JP2016216493A JP 2016216493 A JP2016216493 A JP 2016216493A JP 2016140167 A JP2016140167 A JP 2016140167A JP 2016140167 A JP2016140167 A JP 2016140167A JP 2016216493 A JP2016216493 A JP 2016216493A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- hepes
- piperazine
- treatment
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
なし。
(i)持続性の抗アナンダミド作用に関係している可能性があり、アヘン剤とは対照的に、顕著な副作用が見られない鎮痛活性;
(ii)プロメタジンについて以前に見出された機序に関係している可能性がある抗腫瘍活性;
(iii)種々のイオンチャネルの調節による可能性がある、細胞膜、特に神経膜の安定化;及び
(iv)脱髄損傷の回復
を含む。
脱髄性疾患:多くの神経線維を覆っているミエリン鞘は、若年期に形成されるリポタンパク質層からなる。CNSにおける希突起膠細胞によって形成されるミエリンは、末梢においてシュワン細胞によって形成されるものとは化学的に及び免疫学的に異なるが、両方のタイプは、神経インパルスが軸索に沿って伝達されるのを促進する同一の機能を果たす。
慢性炎症性脱髄性多発根神経障害(CIDP、Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
CIDPは、末梢運動及び感覚神経を冒す自己免疫神経障害である。症状は、緩徐進行性のしびれ及び刺痛であり、通常、両足に始まるが、後に両脚及び両手に広がる。患者はまた、いくらかの衰弱を訴え、この場合も通常、下肢に始まるが、間もなく同様に上肢を含む。感覚系のさらなる関与で、バランスなどの他の種類の感覚が冒され、患者は、暗所において歩く又はバランスを維持することができないと訴える。通常、腸又は膀胱の関与はない。稀に、脳神経に影響を及ぼし、次いで症状は、嚥下困難から顔に生じるしびれを伴う複視にまで及ぶ。認知技能は、CIDPの影響を受けない。
米国特許第5,248,680号明細書:臨床状態の治療に使用するための両性イオン化合物及びそれらのN−ハロ誘導体。
米国特許第5,716,959号明細書:疾患をピペラジン両性イオン化合物で治療する方法。
米国特許出願第20090149464号:神経変性疾患の治療における1,4−ビス(3−アミノアルキル)ピペラジン誘導体の使用。
Claims (7)
- 対象において、脱髄を伴う1若しくは2種以上の神経変性疾患を治療するための医薬組成物であって、前記1若しくは2種以上の神経変性疾患、1若しくは2種以上の脱髄性疾患又は両方を治療するのに十分な量で、滅菌水、緩衝液、生理食塩水又は他の薬学的に許容される担体中に溶解しているN−2−ヒドロキシ−エチル−ピペラジン−N’−2−エタンスルホン酸(HEPES)又はその誘導体を含む医薬組成物。
- 1若しくは2種以上の任意選択の賦形剤、希釈剤、徐放剤若しくは制御放出剤、着色剤、保存剤又はそれらの任意の組合せをさらに含む、請求項1に記載の医薬組成物。
- 脱髄性疾患を伴う1又は2種以上の神経変性疾患が、多発性硬化症、横断性脊髄炎、デビック病、進行性多病巣性白質脳症、視神経炎、白質ジストロフィー、ギラン−バレー症候群、シャルコー−マリー−ツース病、パーキンソン病、アルパース病、ルーゲーリッグ病、大脳皮質基底核変性症、クロイツフェルト−ヤコブ病、前頭側頭葉変性症、ハンチントン病、クラッベ病、多系統萎縮症、ピック病、原発性側索硬化症、進行性核上性麻痺、レフサム病、サンドホフ病、シルダー病、脊髄性筋萎縮症、スティール−リチャードソン−オルスゼフスキー病;脳性麻痺、トゥレット症候群、舞踏病、アテトーシス、双極性障害、統合失調症を含む神経精神障害;又はそれらの任意の組合せを含む、請求項1又は2に記載の組成物。
- HEPESが、経口、皮下、非経口、静脈内、腹膜内又は筋肉内投与のための注射用の滅菌水中に溶解している、請求項1〜3のいずれかに記載の組成物。
- 1日1回、体重を基準として10〜100mg/kgで投与される、請求項1〜4のいずれかに記載の組成物。
- ミエリン鞘を復元、修復及び/又は再生させることによって、1又は2種以上の脱髄性疾患を治療する、請求項1〜5のいずれかに記載の組成物。
- 1若しくは2以上の任意選択の賦形剤、希釈剤、徐放剤若しくは制御放出剤、着色剤、保存剤又はそれらの任意の組合せをさらに含む、請求項1〜6のいずれかに記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24346409P | 2009-09-17 | 2009-09-17 | |
US61/243,464 | 2009-09-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014231168A Division JP5974062B2 (ja) | 2009-09-17 | 2014-11-14 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016216493A true JP2016216493A (ja) | 2016-12-22 |
JP6347807B2 JP6347807B2 (ja) | 2018-06-27 |
Family
ID=43757159
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012529955A Pending JP2013505264A (ja) | 2009-09-17 | 2010-09-17 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
JP2014231168A Active JP5974062B2 (ja) | 2009-09-17 | 2014-11-14 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
JP2015024177A Pending JP2015129150A (ja) | 2009-09-17 | 2015-02-10 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
JP2016140167A Active JP6347807B2 (ja) | 2009-09-17 | 2016-07-15 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012529955A Pending JP2013505264A (ja) | 2009-09-17 | 2010-09-17 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
JP2014231168A Active JP5974062B2 (ja) | 2009-09-17 | 2014-11-14 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
JP2015024177A Pending JP2015129150A (ja) | 2009-09-17 | 2015-02-10 | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 |
Country Status (18)
Country | Link |
---|---|
US (4) | US8883855B2 (ja) |
EP (3) | EP2835133B1 (ja) |
JP (4) | JP2013505264A (ja) |
KR (1) | KR101737775B1 (ja) |
CN (4) | CN109224077A (ja) |
AR (1) | AR078290A1 (ja) |
AU (1) | AU2010295445B2 (ja) |
BR (1) | BR112012006155A2 (ja) |
CA (3) | CA2977918C (ja) |
HK (1) | HK1199621A1 (ja) |
IL (2) | IL218677B (ja) |
IN (1) | IN2012DN02499A (ja) |
MX (2) | MX2012003212A (ja) |
MY (2) | MY174012A (ja) |
NZ (1) | NZ598861A (ja) |
SG (3) | SG179191A1 (ja) |
TW (2) | TWI494106B (ja) |
WO (1) | WO2011035212A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ598861A (en) * | 2009-09-17 | 2013-01-25 | North Texas Medical Ass | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
CN106794168A (zh) | 2014-07-21 | 2017-05-31 | 格利亚有限责任公司 | 用大麻素治疗放疗和化疗相关的认知或情感损伤的方法 |
DK3288637T3 (da) * | 2015-04-28 | 2022-10-17 | Newsouth Innovations Pty Ltd | Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2011491A1 (en) * | 2007-07-05 | 2009-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticonvulsive pharmaceutical compositions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU641529B2 (en) | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
ATE207074T1 (de) | 1995-07-06 | 2001-11-15 | Fraunhofer Ges Forschung | Thiolsilane, verfahren zu deren herstellung und deren verwendung |
US5716959A (en) | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
MXPA00007815A (es) * | 1998-02-11 | 2002-04-24 | Neurochem Inc | Metodo para modular la activacion de macrofagos. |
EP1809288B1 (en) | 2004-11-10 | 2011-09-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
US9308260B2 (en) * | 2007-07-05 | 2016-04-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anticonvulsive pharmaceutical compositions |
EP2163246A1 (en) * | 2008-09-12 | 2010-03-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin |
JP2013504151A (ja) | 2009-09-04 | 2013-02-04 | ビーエーエスエフ ソシエタス・ヨーロピア | 色素増感太陽電池 |
AU2014206220B2 (en) | 2009-09-17 | 2016-09-29 | Bespoke Bioscience, Llc | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
NZ598861A (en) | 2009-09-17 | 2013-01-25 | North Texas Medical Ass | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
-
2010
- 2010-09-17 NZ NZ598861A patent/NZ598861A/xx unknown
- 2010-09-17 AR ARP100103407A patent/AR078290A1/es unknown
- 2010-09-17 TW TW099131755A patent/TWI494106B/zh active
- 2010-09-17 SG SG2012018842A patent/SG179191A1/en unknown
- 2010-09-17 EP EP14191925.8A patent/EP2835133B1/en active Active
- 2010-09-17 SG SG10201500510YA patent/SG10201500510YA/en unknown
- 2010-09-17 CA CA2977918A patent/CA2977918C/en active Active
- 2010-09-17 CN CN201811365002.5A patent/CN109224077A/zh active Pending
- 2010-09-17 US US12/885,404 patent/US8883855B2/en active Active
- 2010-09-17 EP EP10817952.4A patent/EP2477626A4/en not_active Withdrawn
- 2010-09-17 CA CA2774375A patent/CA2774375C/en active Active
- 2010-09-17 AU AU2010295445A patent/AU2010295445B2/en active Active
- 2010-09-17 MY MYPI2015002505A patent/MY174012A/en unknown
- 2010-09-17 CN CN2010800521032A patent/CN102612366A/zh active Pending
- 2010-09-17 KR KR1020127009683A patent/KR101737775B1/ko active IP Right Grant
- 2010-09-17 EP EP19161338.9A patent/EP3520794A3/en active Pending
- 2010-09-17 BR BR112012006155A patent/BR112012006155A2/pt not_active Application Discontinuation
- 2010-09-17 CA CA3122553A patent/CA3122553A1/en active Pending
- 2010-09-17 SG SG10202100421XA patent/SG10202100421XA/en unknown
- 2010-09-17 JP JP2012529955A patent/JP2013505264A/ja active Pending
- 2010-09-17 WO PCT/US2010/049405 patent/WO2011035212A2/en active Application Filing
- 2010-09-17 TW TW103124615A patent/TWI562777B/zh active
- 2010-09-17 MY MYPI2012001195A patent/MY159626A/en unknown
- 2010-09-17 CN CN201410166019.3A patent/CN103977405A/zh active Pending
- 2010-09-17 CN CN201710494640.6A patent/CN107260740A/zh active Pending
- 2010-09-17 MX MX2012003212A patent/MX2012003212A/es active IP Right Grant
- 2010-09-17 MX MX2015008916A patent/MX360190B/es unknown
-
2012
- 2012-03-15 IL IL218677A patent/IL218677B/en active IP Right Grant
- 2012-03-22 IN IN2499DEN2012 patent/IN2012DN02499A/en unknown
-
2014
- 2014-09-09 US US14/481,582 patent/US9867820B2/en active Active
- 2014-11-14 JP JP2014231168A patent/JP5974062B2/ja active Active
-
2015
- 2015-01-06 HK HK15100074.2A patent/HK1199621A1/xx unknown
- 2015-02-10 JP JP2015024177A patent/JP2015129150A/ja active Pending
-
2016
- 2016-07-15 JP JP2016140167A patent/JP6347807B2/ja active Active
-
2017
- 2017-10-04 US US15/725,007 patent/US10213425B2/en active Active
-
2019
- 2019-01-01 IL IL264055A patent/IL264055A/en unknown
- 2019-01-14 US US16/247,233 patent/US20190142825A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2011491A1 (en) * | 2007-07-05 | 2009-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticonvulsive pharmaceutical compositions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6347807B2 (ja) | 疼痛制御及び脱髄損傷の回復におけるn−2−ヒドロキシ−エチル−ピペラジン−n’−2−エタンスルホン酸(hepes)の役割 | |
US20210023061A1 (en) | Use of riluzole prodrugs to treat ataxias | |
AU2016228315B2 (en) | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury | |
AU2014206220B2 (en) | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury | |
Chaudhuri et al. | Movement disorders in clinical practice | |
CN116134048A (zh) | 用于治疗神经精神障碍的组合物和方法 | |
Kapetanovic et al. | Hemorrhagic stroke in a patient recently started on mixed amphetamine salts | |
JPWO2009147831A1 (ja) | 精神障害の治療方法および治療用医薬組成物 | |
Sood et al. | Pharmacotherapeutic challenges in the management of attention-deficit/hyperactivity disorder and chronic tics in a school aged child | |
Gül et al. | Methylphenidate-induced glaucoma in a 13-year-old case | |
Howard et al. | Neurological diseases and emergencies | |
Greene | Dystonia: Part | |
Venables et al. | Case presentations in neurology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170828 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170911 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180529 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6347807 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |